ClinicalTrials.gg
CompletedNCT04893733VIBAKIUpdated Jan 30, 2025

Intravenous Administration of Vitamin B Complex Improves Renal Recovery in Patients with AKI

A Phase 4 interventional study of Vitamin B Complex and STOP AKI protocol in Acute Kidney Injury, sponsored by Caja Nacional de Salud. Completed at 1 site in Bolivia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-01-30.

Sponsored by Caja Nacional de Salud · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2020, registered May 2021).
Phase
Phase 4
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Animal and human studies have shown that the administration of vitamin B3 (niacin) improves renal ischemia; helping to recover from acute kidney injury (AKI) more effectively; Therefore, its use in patients with AKI could improve short-term outcomes: accelerating the recovery of renal function, reducing the days of hospital stay and costs; as well as reducing the incidence of chronic kidney disease (CKD) or progression of CKD after an episode of AKI.

Our main objective is to determine the usefulness of the administration of vitamin B complex as a treatment for established acute kidney injury and its effect on short and long-term outcomes.

02

Conditions studied

  • Acute Kidney Injury

Keywords

  • Acute Kidney Injury
  • Vitamin B complex
  • Creatinine
  • Proteinuria
03

In context

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 395 are open to participants now.

This study's enrollment of 260 is above the median of 100 across 817 interventional studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

This is the only study on the registry with Caja Nacional de Salud as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age who meet modified KDIGO criteria for Acute Kidney Injury, based on serum creatinine or urinary volume criteria.

Exclusion criteria

Exclusion Criteria:

  • Patient under 18 years of age
  • Patients with stage G5 chronic kidney disease
  • Patients with chronic kidney replacement therapy.
  • Pregnant women
  • Transplant patients
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    Vitamin B complex

    Randomized patients with AKI to this arm will received during 5 consecutive days IV Vitamin B complex each 12 hours.

    Drug: Vitamin B Complex · Other: STOP AKI protocol

Interventions

  • Patients with established AKI will be randomized to received IV vitamin B complex each 1 hours for 5 consecutive days versus placebo. Every patients will also received Institution standard of care for AKI

    Also known as: Complejo B Vimin

  • OtherSTOP AKI protocol

    STOP AKI protocols includes: S: identify and treat sepsis. Standard measures should be followed to decrease the risk of infection. Close surveillance to identify early signs of infection with appropriate treatment T: avoid nephrotoxins. Avoidance of drugs harmful to the kidneys (e.g. NSAIDs, gentamicin) Care with intravenous iodinated contrast O: optimize blood pressure and optimize volume status. Avoid dehydration e.g. confused patient. Treat hypovolaemia promptly. Consider with-holding patient anti-hypertensives/diuretics until assessed after major surgery or if patient develops sepsis/hypovolemia P: Prevent harm. Identify the cause promptly and manage appropriately to prevent progression. Prevent complications by instituting prompt therapy. Identify drugs excreted through the kidneys and adjust drug doses promptly if AKI develops. Review fluid management plans to prevent inadequate or excessive intravenous fluid administration

06

What researchers measure

Primary outcomes

  1. Complete renal recovery

    Serum creatinine (CrS) level returns to its baseline value or to a lower value.

    Time frame: Day 7

Secondary outcomes

  1. Progression to Acute Kidney Disease (AKD)

    A eGFR \< than 60 ml/m/1.73m2

    Time frame: 1 month

  2. De novo chronic kidney disease (CKD)

    An eGFR \< than 60 ml/m/1.73m2

    Time frame: 3 months

  3. Progression of CKD

    Patients progresses from a lower KDIGO CKD stage to a higher CKD stage

    Time frame: 3 months

07

Study locations

1 site
  • Hospital Obrero No 2 - C.N.S.
    Cochabamba, 0, Bolivia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893733
Lead sponsor
Caja Nacional de Salud
Collaborators
International Society of Nephrology
Responsible party
Rolando Claure-Del Granado, MD (Head Division of Nephrology, Caja Nacional de Salud) — Principal investigator
First posted
May 19, 2021
Start date
Sep 1, 2020
Primary completion
Dec 30, 2021
Completion
Apr 30, 2022
Last update
Jan 30, 2025

Study contacts

Rolando Claure-Del Granado, M.D.
principal investigator · Hospital Obrero No 2 - C.N.S.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vitamin B Complex

Start the discussion